Steroid treatment to reduce inflammation in active MS lesions
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This Phase 2 study tests whether corticosteroid medicine can reduce inflammation at the edge of active multiple sclerosis (MS) plaques seen on MRI. It may help calm “hot” areas in the brain where MS activity is happening.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (age 18 or older) with multiple sclerosis
- Your screening brain MRI shows an “active” lesion with gadolinium rim/edge changes
- You can consent to the study and complete required visits, exams, and scans
- You can have MRI safely (no incompatible implants/metal or needed removals) and can tolerate the scanner
- You have not taken steroid pills/IV steroids within the last 30 days
- If you could become pregnant, you agree to use birth control; you are not pregnant and not breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special PET-MRI scan to look at brain inflammation in people with relapsing-remitting multiple sclerosis (RRMS). It may help researchers understand how inflammation changes when starting a stronger MS treatment.
This study uses brain scans to look for hidden inflammation in people with multiple sclerosis who have not yet started a strong treatment. It aims to understand how this inflammation affects the disease and to help guide future therapies.
This early-phase study uses a special PET scan and an MRI to look at nerve-related inflammation in people with multiple sclerosis (MS). The goal is to see whether this scan can detect MS-related changes, which could improve how MS is studied in the future.
This trial compares scan results in people with multiple sclerosis or related demyelinating conditions versus people without inflammatory demyelinating diseases. The goal is to better understand what’s happening in the brain and how sex differences may play a role.
This study tests whether a medicine that targets a specific brain inflammation marker (TSPO) can help in people with certain types of multiple sclerosis. It focuses on safety and whether the target can be measured and influenced during treatment.
This study tests an experimental drug called RO7121932 in people with multiple sclerosis. The goal is to see how safe it is and how the body processes it. It might help by offering a new way to manage the condition.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.